Avid Bioservices Inc (CDMO): Cancer Immunotherapy Movers: Bristol-Mye...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	17
Posts	735
Boards Moderated	0
Alias Born	02/05/2004

semper

Re: None

Saturday, 07/04/2015 10:23:18 PM

Saturday, July 04, 2015 10:23:18 PM

Cancer Immunotherapy Movers: Bristol-Myers Squibb Co, Merck & Co, Novartis AG Must Look Out For Smaller Players
Senior equity analyst George Zavoico weighs in on the different cancer immunotherapy market players in an interview to the Life Sciences Report

Among other companies currently pursuing immune checkpoint targeting drugs, Mr. Zavoico mentioned Peregrine Pharmaceuticals (NASDAQ:PPHM). The drug-maker’s antibody bavituximab targets phosphatidylserine (PS), and is in final stage testing to treat non-small cell lung cancer (NSCLC). He also said that since PS is now recognized as an upstream checkpoint inhibitor and could be used alongside Yervoy, Keytruda or Opdivo. Peregrine has also initiated a Phase 1 trial testing bavituximab with Yervoy to treat advanced melanoma, and also intends to conduct a Phase 2 trial to test its drug with Opdivo to treat NSCLC.

http://www.bidnessetc.com/46386-cancer-immunotherapy-movers-bristolmyers-squibb-co-merck-co-novartis-ag-mu/